-$0.28 Earnings Per Share Expected for Strongbridge Biopharma plc (NASDAQ:SBBP) This Quarter

Equities analysts predict that Strongbridge Biopharma plc (NASDAQ:SBBP) will announce earnings of ($0.28) per share for the current quarter, according to Zacks Investment Research. Five analysts have issued estimates for Strongbridge Biopharma’s earnings, with the highest EPS estimate coming in at ($0.25) and the lowest estimate coming in at ($0.30). Strongbridge Biopharma posted earnings per share of ($0.47) in the same quarter last year, which indicates a positive year over year growth rate of 40.4%. The company is scheduled to announce its next quarterly earnings results on Wednesday, October 30th.

On average, analysts expect that Strongbridge Biopharma will report full-year earnings of ($1.01) per share for the current fiscal year, with EPS estimates ranging from ($1.04) to ($0.98). For the next fiscal year, analysts forecast that the company will post earnings of ($0.86) per share, with EPS estimates ranging from ($1.00) to ($0.62). Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that cover Strongbridge Biopharma.

Strongbridge Biopharma (NASDAQ:SBBP) last issued its quarterly earnings data on Wednesday, July 31st. The biotechnology company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.01. Strongbridge Biopharma had a net margin of 181.52% and a return on equity of 49.92%. The business had revenue of $6.08 million during the quarter, compared to analysts’ expectations of $4.82 million.

Several brokerages have weighed in on SBBP. ValuEngine upgraded shares of Strongbridge Biopharma from a “strong sell” rating to a “sell” rating in a research note on Wednesday, October 2nd. Evercore ISI initiated coverage on shares of Strongbridge Biopharma in a report on Tuesday, September 24th. They issued an “outperform” rating on the stock. HC Wainwright reissued a “buy” rating on shares of Strongbridge Biopharma in a report on Thursday, August 1st. Zacks Investment Research lowered shares of Strongbridge Biopharma from a “buy” rating to a “hold” rating in a report on Friday, August 2nd. Finally, Jefferies Financial Group initiated coverage on shares of Strongbridge Biopharma in a report on Tuesday, September 24th. They issued a “buy” rating and a $8.00 target price on the stock. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the stock. Strongbridge Biopharma presently has a consensus rating of “Hold” and a consensus price target of $9.90.

A number of hedge funds have recently added to or reduced their stakes in the business. Alambic Investment Management L.P. bought a new stake in shares of Strongbridge Biopharma during the 2nd quarter valued at approximately $66,000. River & Mercantile Asset Management LLP bought a new stake in shares of Strongbridge Biopharma during the 2nd quarter valued at approximately $1,445,000. D. E. Shaw & Co. Inc. grew its holdings in shares of Strongbridge Biopharma by 25.5% during the 2nd quarter. D. E. Shaw & Co. Inc. now owns 950,081 shares of the biotechnology company’s stock valued at $2,973,000 after purchasing an additional 192,760 shares during the last quarter. Vivo Capital LLC bought a new stake in Strongbridge Biopharma during the 1st quarter worth approximately $4,552,000. Finally, JPMorgan Chase & Co. bought a new stake in Strongbridge Biopharma during the 2nd quarter worth approximately $42,000. 52.25% of the stock is currently owned by hedge funds and other institutional investors.

Strongbridge Biopharma stock traded down $0.06 during midday trading on Friday, hitting $2.01. The company’s stock had a trading volume of 141,611 shares, compared to its average volume of 231,540. Strongbridge Biopharma has a 1-year low of $2.02 and a 1-year high of $6.52. The company has a 50-day moving average price of $2.54 and a two-hundred day moving average price of $3.21. The company has a market cap of $116.50 million, a price-to-earnings ratio of 6.48 and a beta of 0.81.

About Strongbridge Biopharma

Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company's commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency.

Recommended Story: What is the formula for the cash asset ratio?

Get a free copy of the Zacks research report on Strongbridge Biopharma (SBBP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.